COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:COLL • US19459J1043

48.18 USD
+0.67 (+1.41%)
At close: Feb 4, 2026
48.18 USD
0 (0%)
After Hours: 2/4/2026, 8:11:55 PM
Fundamental Rating

6

Taking everything into account, COLL scores 6 out of 10 in our fundamental rating. COLL was compared to 191 industry peers in the Pharmaceuticals industry. COLL has an excellent profitability rating, but there are some minor concerns on its financial health. COLL may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make COLL a good candidate for value investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year COLL was profitable.
  • In the past year COLL had a positive cash flow from operations.
  • Of the past 5 years COLL 4 years were profitable.
  • Each year in the past 5 years COLL had a positive operating cash flow.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • COLL's Return On Assets of 3.64% is amongst the best of the industry. COLL outperforms 83.77% of its industry peers.
  • COLL has a better Return On Equity (21.27%) than 91.10% of its industry peers.
  • COLL's Return On Invested Capital of 9.10% is amongst the best of the industry. COLL outperforms 87.96% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for COLL is in line with the industry average of 12.83%.
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROIC 9.1%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

  • COLL has a better Profit Margin (7.72%) than 82.20% of its industry peers.
  • COLL's Profit Margin has declined in the last couple of years.
  • COLL has a Operating Margin of 20.74%. This is amongst the best in the industry. COLL outperforms 89.01% of its industry peers.
  • In the last couple of years the Operating Margin of COLL has grown nicely.
  • COLL's Gross Margin of 57.22% is fine compared to the rest of the industry. COLL outperforms 68.59% of its industry peers.
  • In the last couple of years the Gross Margin of COLL has grown nicely.
Industry RankSector Rank
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
  • The number of shares outstanding for COLL has been reduced compared to 1 year ago.
  • The number of shares outstanding for COLL has been reduced compared to 5 years ago.
  • The debt/assets ratio for COLL has been reduced compared to a year ago.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.50, we must say that COLL is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.50, COLL is in line with its industry, outperforming 56.02% of the companies in the same industry.
  • COLL has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as COLL would need 2.79 years to pay back of all of its debts.
  • COLL's Debt to FCF ratio of 2.79 is amongst the best of the industry. COLL outperforms 91.10% of its industry peers.
  • A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
  • COLL has a worse Debt to Equity ratio (2.71) than 80.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Altman-Z 1.5
ROIC/WACC0.97
WACC9.36%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • A Current Ratio of 1.36 indicates that COLL should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.36, COLL is not doing good in the industry: 73.82% of the companies in the same industry are doing better.
  • COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL's Quick ratio of 1.27 is on the low side compared to the rest of the industry. COLL is outperformed by 70.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.27
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.73%, which is quite impressive.
  • Measured over the past years, COLL shows a very strong growth in Earnings Per Share. The EPS has been growing by 154.78% on average per year.
  • The Revenue has grown by 26.34% in the past year. This is a very strong growth!
  • COLL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.31% yearly.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%

3.2 Future

  • Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -1.58% on average per year.
  • The Revenue is expected to grow by 3.62% on average over the next years.
EPS Next Y18.1%
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 6.70 indicates a rather cheap valuation of COLL.
  • Based on the Price/Earnings ratio, COLL is valued cheaply inside the industry as 94.24% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 28.25. COLL is valued rather cheaply when compared to this.
  • COLL is valuated cheaply with a Price/Forward Earnings ratio of 5.92.
  • Based on the Price/Forward Earnings ratio, COLL is valued cheaply inside the industry as 93.72% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.50, COLL is valued rather cheaply.
Industry RankSector Rank
PE 6.7
Fwd PE 5.92
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 97.91% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 96.86% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.26
EV/EBITDA 4.98
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • COLL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y12.32%
EPS Next 3Y-0.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for COLL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (2/4/2026, 8:11:55 PM)

After market: 48.18 0 (0%)

48.18

+0.67 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-19
Inst Owners120.33%
Inst Owner Change0.44%
Ins Owners1.42%
Ins Owner Change-0.82%
Market Cap1.52B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.67
Price Target54.23 (12.56%)
Short Float %17.98%
Short Ratio10.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)9.25%
PT rev (3m)19.21%
EPS NQ rev (1m)-3.66%
EPS NQ rev (3m)3.56%
EPS NY rev (1m)-0.9%
EPS NY rev (3m)-16.04%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)5.33%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)4.02%
Valuation
Industry RankSector Rank
PE 6.7
Fwd PE 5.92
P/S 2.01
P/FCF 5.26
P/OCF 5.24
P/B 5.54
P/tB N/A
EV/EBITDA 4.98
EPS(TTM)7.19
EY14.92%
EPS(NY)8.14
Fwd EY16.89%
FCF(TTM)9.15
FCFY19%
OCF(TTM)9.2
OCFY19.1%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.37
PEG (5Y)N/A
Graham Number37.5
Profitability
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROCE 13.6%
ROIC 9.1%
ROICexc 12.09%
ROICexgc N/A
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
FCFM 38.21%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Debt/EBITDA 1.94
Cap/Depr 0.72%
Cap/Sales 0.21%
Interest Coverage 2.17
Cash Conversion 75.92%
Profit Quality 495.01%
Current Ratio 1.36
Quick Ratio 1.27
Altman-Z 1.5
F-Score7
WACC9.36%
ROIC/WACC0.97
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y18.1%
EPS Next 2Y12.32%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year157.27%
EBIT Next 3Y28.14%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%

COLLEGIUM PHARMACEUTICAL INC / COLL FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


What is the profitability of COLL stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.